Aktuelle Systemtherapie des metastasierten malignen Melanoms

Zusammenfassung

Noch bis vor wenigen Jahren galt das metastasierte Melanom als therapierefraktärer Tumor. Die aktuellen Zulassungen der Kombination aus BRAF- und MEK-Inhibitoren sowie der PD-1-Checkpointinhibitoren erweitern das therapeutische Portfolio der Dermatoonkologie für Patienten mit fortgeschrittenem Melanom deutlich. Für die Kombinationstherapien aus BRAF- und MEK-Inhibitoren werden mittlerweile objektive Ansprechraten von bis zu 70 % mit einem medianen Überleben von rund 28 Monaten angegeben. Durch die Therapie mit CTLA-4-Inhibitoren scheinen zudem rund 20 % der Patienten ein Langzeitüberleben zu erreichen. Mit der Verfügbarkeit der PD-1-Inhibitoren erhofft man sich, diesen Anteil der Patienten noch erhöhen zu können. Aktuell liegt das 2-Jahres-Überleben bei rund 40 %. In Zukunft müssen klinische Studien klären, in welcher Sequenz, Kombination und Dauer die einzelnen Substanzen zum Einsatz kommen müssen, um das entscheidende Ziel für den Patienten zu erreichen: Eine Heilung oder zumindest der Übergang in eine langfristige, kontrollierte Erkrankung.

Abstract

Only a few years ago metastatic melanoma was considered as a refractory disease. The latest approvals of the combined therapy of BRAF and MEK inhibitors, as well as the approvals of PD-1 checkpoint inhibitors enhance the therapeutic portfolio in dermatooncology for patients suffering from advanced melanoma significantly. With the combination of BRAF- and MEK-Inhibitors objective response rates of up to 70 % can be achieved with a median survival of about 28 months. Moreover, due to the treatment with CTLA-4 inhibitors about 20 % of patients appear to achieve a long term survival. PD-1 inhibitors are believed to be able to increase this proportion of patients. Right now, the 2-Year overall survival rate reaches approximately 40 %. In the future, clinical trials need to clarify in what sequence, combination and duration of the individual substances must be used in order to achieve the ultimate goal for the patient: cure or at least the transition to a long-term, controlled disease.

• Literatur

• 1 Eigentler T, Caroli U, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003; 4: 748-759
• 2 Davies H, Bignell GR, Cox C. et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954
• 3 Bauer J, Buttner P, Murali R. et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 2011; 24: 345-351
• 4 Shain AH, Yeh I, Kovalyshyn I. et al. The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med 2015; 373: 1926-1936
• 5 McArthur GA, Chapman PB, Robert C. et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; 15: 323-332
• 6 Hauschild A, Grob JJ, Demidov LV. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365
• 7 Flaherty KT, Robert C, Hersey P. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114
• 8 Charles J, Martel C, de Fraipont F. et al. Mechanisms of resistance to anti-BRAF treatments. Ann Dermatol Venereol 2014; 141: 671-681
• 9 Long GV, Stroyakovskiy D, Gogas H. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371: 1877-1888
• 10 Robert C, Karaszewska B, Schachter J. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372: 30-39
• 11 Larkin J, Ascierto PA, Dreno B. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371: 1867-1876
• 12 Mai R, Zhou S, Zhong W. et al. Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials. Oncotarget 2015; 6: 28502-28512
• 13 Hodi FS, O'Day SJ, McDermott DF. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723
• 14 Robert C, Thomas L, Bondarenko I. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526
• 15 Maio M, Grob JJ, Aamdal S. et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 2015; 33: 1191-1196
• 16 Schadendorf D, Hodi FS, Robert C. et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015; 33: 1889-1894
• 17 Wieder T, Brenner E, Braumuller H, Rocken M. Immuntherapie des Melanoms: Wirksamkeit und Wirkungsmechanismen. J Dtsch Dermatol Ges 2016; 14: 28-37
• 18 Robert C, Long GV, Brady B. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330
• 19 Weber JS, D'Angelo SP, Minor D. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375-384
• 20 Hamid O, Robert C, Daud A. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144
• 21 Robert C, Ribas A, Wolchok JD. et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384: 1109-1117
• 22 Ribas A, Puzanov I, Dummer R. et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16: 908-918
• 23 Larkin J, Chiarion-Sileni V, Gonzalez R. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373: 23-34